504 related articles for article (PubMed ID: 19710397)
1. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
2. Unique clinical and biological features of leukemia in Down syndrome children.
Xavier AC; Ge Y; Taub J
Expert Rev Hematol; 2010 Apr; 3(2):175-86. PubMed ID: 21083461
[TBL] [Abstract][Full Text] [Related]
3. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
4. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
5. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
[TBL] [Abstract][Full Text] [Related]
6. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
Malinge S; Izraeli S; Crispino JD
Blood; 2009 Mar; 113(12):2619-28. PubMed ID: 19139078
[TBL] [Abstract][Full Text] [Related]
7. Acute Megakaryocytic Leukemia.
McNulty M; Crispino JD
Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548219
[TBL] [Abstract][Full Text] [Related]
8. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
10. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
11. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
12. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
13. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
14. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
15. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
16. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
[TBL] [Abstract][Full Text] [Related]
17. Myeloid leukemia in Down syndrome.
Khan I; Malinge S; Crispino J
Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
[TBL] [Abstract][Full Text] [Related]
18. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.
Cabelof DC; Patel HV; Chen Q; van Remmen H; Matherly LH; Ge Y; Taub JW
Blood; 2009 Sep; 114(13):2753-63. PubMed ID: 19633202
[TBL] [Abstract][Full Text] [Related]
19. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
[TBL] [Abstract][Full Text] [Related]
20. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
